Welcome to our dedicated page for Brandes International ETF news (Ticker: BINV), a resource for investors and traders seeking the latest updates and insights on Brandes International ETF stock.
Track all official updates and market developments for Brandes International ETF (BINV) through this dedicated news hub. As a value-focused exchange-traded fund targeting global equities, BINV provides investors with exposure to carefully selected international opportunities. This page consolidates press releases, regulatory filings, and strategic announcements to help stakeholders monitor portfolio adjustments and market positioning.
Key resources include: Quarterly earnings commentary, portfolio rebalancing notices, and management insights about international value investing. Investors can access filings detailing expense ratios, asset allocation changes, and dividend distributions alongside analysis of emerging market trends impacting the fund.
Bookmark this page for timely updates on BINV's performance relative to international benchmarks and competitor ETFs. Subscribers receive alerts when new SEC filings or material events are published, ensuring informed monitoring of this international investment vehicle.
Transgene and BioInvent announced that preclinical studies of their oncolytic virus BT-001 will be presented at the AACR Annual Meeting 2022. This innovative therapy targets CTLA-4, showing robust anti-tumoral activity and improved safety compared to traditional treatments. Results indicate BT-001 effectively treats resistant 'cold tumors' and enhances regulatory T cell depletion. The Phase I/IIa clinical study is ongoing, assessing BT-001 alone and with pembrolizumab. Initial data is expected in early 2022.
Transgene and BioInvent announced in a press release that their co-developed product, BT-001, has shown promising preclinical proof-of-concept data, published in the Journal for ImmunoTherapy of Cancer. The study indicates that BT-001 may provide superior therapeutic benefits over conventional anti-CTLA-4 antibodies, with significant reductions in systemic toxicity and enhanced efficacy against ‘cold tumors’. Ongoing Phase 1/2a trials in Europe aim to demonstrate BT-001's effectiveness against solid tumors, with initial data expected in H1 2022.
BioInvent (BINV) and Transgene announced promising preclinical data for their oncolytic virus BT-001, designed to combat solid tumors. The findings indicate significant intratumoral expression of an immune checkpoint inhibitor and strong anti-tumoral activity across various models. Currently in a Phase I/IIa trial, BT-001 aims to enhance treatment efficacy while minimizing systemic exposure. Initial results are expected in the first half of 2022, showcasing BT-001's potential role in cancer immunotherapy.
Transgene and BioInvent announce the presentation of new preclinical data on their BT-001 oncolytic virus at the upcoming Society for Immunotherapy of Cancer (SITC2021) in Washington, D.C., on November 13, 2021. BT-001 is developed to enhance antitumor response while improving safety by targeting the tumor microenvironment. The ongoing Phase I/IIa study in Europe and the U.S. is progressing well, assessing BT-001 as a monotherapy and in combination with pembrolizumab for solid tumors. Initial Phase I results are anticipated in H1 2022.
FAQ
What is the current stock price of Brandes International ETF (BINV)?
